According to a release, FCDI plans to build a $21 million facility for the production of human iPS cell therapy applications that will be operational by March 2020 and address “unmet medical needs” such as age-related macular degeneration, retinitis pigmentosa, Parkinson’s disease, heart diseases, and cancer. FCDI already has labs and offices on Madison’s west side.